Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Success in a Phase III trial in schizophrenia, set to report in Q1 2012, would mean a double filing in mid-2012.

You may also be interested in...

Forest’s Antipsychotic Cariprazine Clears Last Clinical Hurdle To Double NDA Filing In 2012

Specialty pharma has data in hand to support a double filing of novel antipsychotic cariprazine this year for acute exacerbation of schizophrenia and bipolar mania, with studies ongoing to support two additional indications in MDD.

MDD Market Snapshot: Depressing Future For Antidepressants

Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.

Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?

Forest Laboratories, Inc. has late-stage products lined up in its pipeline to help fill the gap left when Lexapro and Namenda go generic, but the burden on a specialty pharma to differentiate its products is a heavy one these days, and it will be a struggle to the finish to convince investors the cup is half full.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts